Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
HIV, Gilead
Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs
(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court. The settlement follows a victory for Gilead in a 2023 jury trial on the government's patent infringement allegations.
Biden administration and Gilead settle long-running battle over patents for HIV PrEP pills
After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a pair of HIV prevention pills.
Gilead reportedly settles CDC patent dispute over HIV drugs
Gilead Sciences (NASDAQ:GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and Descovy. The lawsuit stemmed from research Gilead (NASDAQ:GILD) conducted with the U.
The New Republic on MSN
7h
The Supreme Court Could Reignite an HIV Crisis
The next chapter of the right-wing war on the Affordable Care Act involves a case that targets the preventative care that ...
16h
HIV pioneers are aging faster than normal, prompting new approaches to care
But just seven years ago, and despite living with HIV for nearly half his life, Duffy was remarkably healthy, working in ...
Rolling Out
2d
How new HIV prevention strategies are changing lives
Discover the latest advancements in HIV prevention and how they offer hope for reducing infections, especially in the Black ...
2d
New Report Shows Link Between Ending HIV And Upholding Human Rights
Here are some of the findings from UNAIDS' new report on HIV and human rights, and what they could mean for the fight against ...
12d
on MSN
HIV in 2025: 'There Is Hope for the Future,' Say Disease Experts
Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...
The American Journal of Managed Care
1d
Patients With HIV May Have High Prevalence of Long COVID
Although the association between HIV and long COVID was inconclusive, the prevalence of long COVID in patients with HIV was ...
Hosted on MSN
1h
HIV-positive Palestinians in Gaza have run out of medication: ‘There is nothing left’
A new report has shed light on the struggles of HIV-positive Palestinians living in Gaza, where medication is running out.
5d
Why are so many Indigenous Panamanians contracting HIV — and dying of AIDS?
The government provides HIV medicines free of charge. Yet in one Indigenous territory, cases and deaths are increasing at an ...
Medscape
2d
Two-Drug HIV Regimen Matches Three-Drug Options in Long-Term Treatment Success
Among treatment-naive people with HIV, dolutegravir/lamivudine showed viral suppression comparable with those of other ...
ABC 11 Raleigh NC on MSN
21h
Duke researchers achieve breakthrough in HIV vaccine development
Scientists at Duke University's Human Vaccine Institute have made a significant advance in the quest for an HIV vaccine.
1d
on MSN
HIV vaccine candidate activates crucial immune function
Researchers at the Duke Human Vaccine Institute successfully created an HIV vaccine candidate that guides key immune cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Gilead Sciences
Gaza
Feedback